MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–1260. doi:10.1097/JTO.0000000000000630.
   PubMed Web of Science ®Google Scholar
• Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52:103–109. doi:10.1016/j.semcancer.2017.11.019.
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz J-C, Zhu C-Q, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144. doi:10.1056/NEJMoa050736.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98:1817–1824. doi:10.1111/j.1349-7006.2007.00607.x.
   PubMed Web of Science ®Google Scholar
• Soda M, Schmid KJ, Laoueillé-Duprat S, Pien S, Escobar-Restrepo J-M, Baroux C, Gagliardini V, Page DR, Wolfe KH, Grossniklaus U. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566. doi:10.1038/nature05945.
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. doi:10.1126/science.1099314.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550. doi:10.1038/nature13385.
   PubMed Web of Science ®Google Scholar
• Rehman SSU, Ramalingam SS. Metastatic Lung Cancer: emerging Therapeutic Strategies. Semin Respir Crit Care Med. 2016;37:736–749. doi:10.1055/s-0036-1592111.
   PubMed Web of Science ®Google Scholar
• Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924–3933. doi:10.1200/JCO.2017.74.3062.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Mikropoulos C, Bancroft EK, Dadaev T, Goh C, Taylor N, Saunders E, Borley N, Keating D, Page EC, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21:634–642. doi:10.1634/theoncologist.2015-0507.
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Postel-Vinay S, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann Oncol. 2016;27:2004–2016. doi:10.1093/annonc/mdw321.
   PubMed Web of Science ®Google Scholar
• Ventola CL. Cancer immunotherapy, part 3: challenges and future trends. P T. 2017;42:514–521.
   PubMedGoogle Scholar
• Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sørensen M, Meldgaard P, Hager H. PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy. Transl Oncol. 2016;9:64–69. doi:10.1016/j.tranon.2016.01.003.
   PubMed Web of Science ®Google Scholar
• Sun JM, Zhou W, Choi Y-L, Choi S-J, Kim SE, Wang Z, Dolled-Filhart M, Emancipator K, Wu D, Weiner R, et al. Prognostic significance of PD-L1 in patients with non-small cell lung cancer: a large cohort study of surgically resected cases. J Thorac Oncol. 2016;11:1003–1011. doi:10.1016/j.jtho.2016.04.007.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Chizema-Kawesha E, Blake A, Chewe O, Mwaba J, Zulu G, Poncin M, Rakesh A, Page A-L, Stoitsova S, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–2104. doi:10.1056/NEJMoa1801946.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van Den Heuvel MM, Ciuleanu T-E, Badin F, et al. First-line nivolumab in stage Iv or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376:2415–2426. doi:10.1056/NEJMoa1613493.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34. doi:10.1186/s13073-017-0424-2.
   PubMed Web of Science ®Google Scholar
• Goodman AM, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598–2608. doi:10.1158/1535-7163.MCT-17-0386.
   PubMed Web of Science ®Google Scholar
• Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, Oliver N, MacConaill L, Ducar M, et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016;8:79. doi:10.1186/s13073-016-0333-9.
   PubMed Web of Science ®Google Scholar
• Campesato LF, Barroso-Sousa R, Jimenez L, Correa BR, Sabbaga J, Hoff PM, Reis LFL, Galante PAF, Camargo AA. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget. 2015;6:34221–34227. doi:10.18632/oncotarget.5950.
   PubMedGoogle Scholar
• Heeke S, Hofman P. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? Transl Lung Cancer Res. 2018;7:631–638. doi:10.21037/tlcr.2018.08.04.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD, Chaudhary N, Page A, Smith D, Thompson J, Vinicius L, Mace R, Migliano AB. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74. doi:10.1126/science.aaa4971.
   PubMed Web of Science ®Google Scholar
• Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017;7:264–276. doi:10.1158/2159-8290.CD-16-0828.
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–866. doi:10.1038/nrc1997.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Berindan-Neagoe I, Monroig Pdel C, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014;64:311–336. doi:10.3322/caac.21244.
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–469. doi:10.1016/j.molmed.2014.06.005.
   PubMed Web of Science ®Google Scholar
• Dragomir M, Chen B, Fu X, Calin GA. Key questions about the checkpoint blockade-are microRNAs an answer? Cancer Biol Med. 2018;15:103–115. doi:10.20892/j.issn.2095-3941.2018.0006.
   PubMed Web of Science ®Google Scholar
• Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol. 2016;16:279–294. doi:10.1038/nri.2016.40.
   PubMed Web of Science ®Google Scholar
• Xiao PX, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, et al. 536PCorrelation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild type advanced NSCLC. Ann Oncol. 2018:29. doi:10.1093/annonc/mdy425.046.
   PubMed Web of Science ®Google Scholar
• Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71. doi:10.1093/nar/gkv1507.
   PubMed Web of Science ®Google Scholar
• Cibulskis K, Hu Y-C, Markoulaki S, Welstead GG, Cheng AW, Shivalila CS, Pyntikova T, Dadon DB, Voytas DF, Bogdanove AJ, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–219. doi:10.1038/nbt.2514.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Hellmann MD, Awad MM, Borghaei H, Gainor J, Brahmer J, Spigel DR, Reck M, O’Byrne KJ, Paz-Ares L, et al. Abstract CT078: tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568. Cancer Res. 2018;78:CT078–CT078.
   Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi:10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Szekely GJ, Rizzo ML. Hierarchical clustering via joint between-within distances: extending ward’s minimum variance method. J Classification. 2005;22:151–183. doi:10.1007/s00357-005-0012-9.
   Web of Science ®Google Scholar
• Wu TT, Chen YF, Hastie T, Sobel E, Lange K. Genome-wide association analysis by lasso penalized logistic regression. Bioinformatics. 2009;25:714–721. doi:10.1093/bioinformatics/btp041.
   PubMed Web of Science ®Google Scholar
• Friedman JH, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:22. doi:10.18637/jss.v033.i01.
   Web of Science ®Google Scholar
• Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. doi:10.1186/1471-2105-12-77.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33:853–861 e854. doi:10.1016/j.ccell.2018.04.001.
   PubMed Web of Science ®Google Scholar
• Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15:R29. doi:10.1186/gb-2014-15-2-r29.
   PubMed Web of Science ®Google Scholar
• Yang JH, Li J-H, Shao P, Zhou H, Chen Y-Q, Qu L-H. starBase: a database for exploring microRNA-mRNA interaction maps from argonaute CLIP-seq and degradome-seq data. Nucleic Acids Res. 2011;39:D202–209. doi:10.1093/nar/gkq1056.
   PubMed Web of Science ®Google Scholar
• Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T, Hatzigeorgiou AG. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 2015;43:W460–466. doi:10.1093/nar/gkv403.
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25:25–29. doi:10.1038/75556.
   PubMed Web of Science ®Google Scholar
• Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos I-L, Maniou S, Karathanou K, Kalfakakou D, et al. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA: mRNAinteractions. Nucleic Acids Res. 2015;43:D153–159. doi:10.1093/nar/gku1215.
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845.
   PubMed Web of Science ®Google Scholar
• Koeppel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E, Rouleau E, Solary E, Soria J-C, André F, et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017;12:e0188174. doi:10.1371/journal.pone.0188174.
   PubMed Web of Science ®Google Scholar
• Davis AA, Chae YK, Agte S, Pan A, Simon NI, Taxter TJ, Behdad A, Carneiro BA, Cristofanilli M, Giles FJ. Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA). J Clin Oncol. 2017;35:e23028–e23028. doi:10.1200/JCO.2017.35.15_suppl.e23028.
   Web of Science ®Google Scholar
• Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24:1441–1448. doi:10.1038/s41591-018-0134-3.
   PubMed Web of Science ®Google Scholar
• Fabrizio D, Lieber D, Malboeuf C, Silterra J, White E, Coyne M, Brennan T, Ma J, Kennedy M, Schleifman E, et al. Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab. Cancer Res. 2018;78:5706. doi:10.1158/1538-7445.am2018-5706.
   PubMed Web of Science ®Google Scholar
• Fenizia F, Pasquale R, Roma C, Bergantino F, Iannaccone A, Normanno N. Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. Transl Lung Cancer Res. 2018;7:668–677. doi:10.21037/tlcr.2018.09.23.
   PubMed Web of Science ®Google Scholar
• Cortez MA, Anfossi S, Ramapriyan R, Menon H, Atalar SC, Aliru M, Welsh J, Calin GA. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019;58:244–253. doi:10.1002/gcc.22725.
   PubMed Web of Science ®Google Scholar
• Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Galeone C, Verri C, Mensah M, Centonze G, Martinetti A, et al. Circulating miRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective study. Clin Cancer Res. 2019;25:2166–2173. doi:10.1158/1078-0432.CCR-18-1981.
   PubMed Web of Science ®Google Scholar